Company Overview - InnoCare aims to become a global biopharmaceutical leader, focusing on oncology and autoimmune diseases[6, 7, 8] - The company has raised a total of $134 billion USD since its founding in 2015[11] - InnoCare has a fully-integrated drug innovation platform with 13 clinical products in the pipeline and 2 marketed products[13] Orelabrutinib (BTKi) - Orelabrutinib demonstrates ~100% BTK occupation at 50 mg QD and above, with an improved safety profile[23] - Orelabrutinib has shown an 83% overall response rate (ORR) in r/r MCL patients and a 589% ORR in r/r MZL patients[34] - A Phase III registrational trial for Orelabrutinib is ongoing in China for SLE[52] ICP-332 (TYK2 Inhibitor) - ICP-332, at 80mg QD, achieved a 782% reduction from baseline in EASI score in Atopic Dermatitis (AD) patients[75] - 88% of patients achieved EASI 50 and 72% achieved EASI 75 at Week 4 with ICP-332 treatment[75] - Global AD market is expected to reach $222 billion USD by 2028[71] Portfolio Expansion - Tafasitamab BLA submission in China is planned for 2024Q2, targeting 160,000 new DLBCL patients globally per annum[46] - ICP-248 (BCL-2 inhibitor) showed 100% efficacy (6 out of 6 patients) in early clinical results[41] - InnoCare plans to submit an NDA for 1L CLL/SLL in China and r/r MCL in the USA for Orelabrutinib in the second half of 2024[102]

Financial Performance Highlights - Revenue reached RMB 41,067 million, a year-on-year decrease of 080%[5] - R&D expense was RMB 3,644 million, a year-on-year decrease of 1615%[6] - Net profit attributable to shareholders was RMB 2,770 million, a year-on-year increase of 1608%[7] - Net operating cash flow reached RMB 4,470 million, a year-on-year increase of 3113%[6] Key Products and R&D - Serplulimab Injection (PD-1) achieved revenue of RMB 1,313 million in 2024[68, 130] - Pharma R&D expenditure was RMB 4,910 million, accounting for 1698% of Pharma revenue[63, 67] - Axicabtagene Ciloleucel Injection has benefited over 800 patients since approval in 2021[43, 75, 132] Global Operations and Internationalization - Revenue from countries and regions outside Chinese mainland reached RMB 11,297 million, a year-on-year increase of 893%[30] - Sisram's direct sales revenue increased to 87%[36, 100] Medical Devices - Sisram Medical's revenue was USD 3590 million in 2024[99] - 58 Da Vinci Surgical Systems were installed in China in 2024[108] Sinopharm Performance - Pharmaceutical distribution segment revenue recorded RMB 444,365 million, a year-on-year increase of 075%[121] - Medical device distribution segment revenue recorded RMB 117,915 million, a year-on-year decrease of 944%[121] - Retail pharmacy segment revenue recorded RMB 35,981 million, a year-on-year increase of 082%[121]

Financial Performance - Revenue reached RMB 9,420 million, a decrease of 726% year-over-year[6] - R&D expense was RMB 737 million, down 1110% year-over-year[7] - Net profit attributable to shareholders was RMB 765 million, an increase of 2542% year-over-year[8] - Net operating cash flow increased to RMB 1,056 million, up 1508% year-over-year[7] - 2024 Pharma R&D expenditure was RMB 4,910 million, accounting for 1698% of Pharma revenue[61] Key Products & Pipelines Progress - Serplulimab Injection (PD-1) received EMA approval for ES-SCLC treatment[12] - Tenapanor Hydrochloride Tablets approved by NMPA for serum phosphorus control in adult dialysis patients with chronic kidney disease[13] - Fosun Pharma achieved a revenue of RMB 11,297 million (+893% YoY) from countries and regions outside Chinese mainland in 2024[26] Med Tech Segment - Med Tech segment revenue reached RMB 4,390 million[87] - Sisram Medical's revenue was USD 3590 million in 2024[96] Healthcare Services - Healthcare Services segment revenue was RMB 6,672 million[108] Sinopharm Performance - Pharmaceutical distribution segment revenue recorded RMB 444,365 million (+075% YoY)[116] - Medical device distribution segment revenue recorded RMB 117,915 million (-944% YoY)[116] - Revenue of the retail pharmacy segment recorded RMB 35,981 million (+082% YoY)[116]

Financial Performance Highlights - The group's insurance revenue reached RMB 537709 million, a 67% increase compared to 2023[103, 104] - Net profit attributable to equity holders of the company increased by 888% to RMB 42151 million[20, 104] - Total investment income increased significantly by 862% to RMB 822 billion[41, 87] - The group's total assets increased by 135% to RMB 1766321 million[26, 104] - The annual cash dividend per share increased by 154% to RMB 0180[28] Segment Performance - PICC P&C's insurance revenue increased by 61% to RMB 485223 million[103, 104] - PICC Life's insurance revenue increased by 230% to RMB 22384 million[103, 104] - PICC Health's insurance revenue increased by 62% to RMB 27217 million[103, 104] Key Initiatives and Innovation - Green insurance provided risk protection of RMB 184 trillion[33, 53] - Technology insurance provided risk protection of RMB 31 trillion[33] - Premiums from products dedicated to technological activities increased by 180%[65]

Financial Performance Summary - The company's turnover decreased by 9.7% year-on-year (YoY), reaching HK$3,941 million[7] - Gross profit decreased by 11.9% YoY, amounting to HK$1,571 million[7] - Recurring profit saw a significant decline of 51.1% YoY, settling at HK$107 million[7] - Profit for the year experienced a substantial decrease of 64.8% YoY, recorded at HK$77 million[7] Regional Performance - Hong Kong & Macau turnover decreased by 12.3% YoY, totaling HK$2,992 million and contributing 75.9% to the group's turnover[8] - Mainland China turnover decreased by 10.5% YoY, reaching HK$520 million and accounting for 13.2% of the group's turnover[8] - Southeast Asia turnover increased by 14.7% YoY, amounting to HK$420 million and representing 10.6% of the group's turnover[8] Operational Adjustments - The company closed 14 offline stores in Mainland China to adjust its operating model[8] - The company will orderly close the remaining 18 offline stores in Mainland China to focus on developing online business[25] - The company added 2 new stores in HK & Macau and 3 new stores in Southeast Asia[20] Cash Flow and Financial Position - Cash inflow from operations was HK$137 million[7] - Cash on hand amounted to HK$371 million, with total available funds of HK$687 million (including undrawn borrowing facilities of HK$316 million)[17] Strategy and Outlook - The company aims to strengthen operational efficiency through curated product portfolio and precise marketing[31] - The company is aiming for growth in both sales and gross profit while maintaining a stable gross profit margin[31]

Financial Performance - Adjusted revenue increased by 3.8% to HK$10.6 billion [13] - Adjusted cash profit was HK$266 million [13] - Net loss attributable to shareholders was approximately HK$1,275 million [22] - Total bank loans and notes decreased by approximately HK$2.4 billion, an 8.6% drop compared to March 31, 2024 [22] - Monetized approximately HK$1.2 billion in non-core assets and businesses in FY2025 [22] Operational Highlights - Property development adjusted revenue increased by 5.3% to approximately HK$7.2 billion [14] - Hotel revenue increased by 2.3% to approximately HK$2.077 billion [16] - Car park revenue decreased by 2.6% to approximately HK$713 million [16] - Gaming revenue increased by 1.6% to approximately HK$409 million [16] Balance Sheet Management - Adjusted net gearing ratio decreased to 67.6% as of March 31, 2025 [22] - Net debt reduced by HK$1.3 billion [29] - Total cumulative attributable presales and unbooked contracted sales reached approximately HK$8.9 billion [14]

Financial Performance - Total operating revenues increased by 10.8% to $1.232 billion in 1Q'25, compared to $1.112 billion in 1Q'24[17] - Gaming revenue increased by 12.2% to $1.024 billion in 1Q'25, compared to $913 million in 1Q'24[17] - Non-gaming revenue increased by 4.4% to $208 million in 1Q'25, compared to $199 million in 1Q'24[17] - Net income increased significantly by 4944.9% to $28 million in 1Q'25, compared to $1 million in 1Q'24[17] - Adjusted Property EBITDA increased by 14.1% to $341 million in 1Q'25, compared to $299 million in 1Q'24[17] Performance by Property - City of Dreams Macau's Adjusted EBITDA increased by 27.5% to $196 million in 1Q'25, compared to $154 million in 1Q'24[17] - Studio City's Adjusted EBITDA increased by 10.7% to $97 million in 1Q'25, compared to $88 million in 1Q'24[17] - Altira recorded a negative Adjusted EBITDA of $1 million in 1Q'25, compared to a positive $1 million in 1Q'24, a decrease of 148.3%[17] - City of Dreams Manila's Adjusted EBITDA decreased by 20.6% to $30 million in 1Q'25, compared to $38 million in 1Q'24[17] - City of Dreams Mediterranean and Other's Adjusted EBITDA increased by 10.2% to $12 million in 1Q'25, compared to $11 million in 1Q'24[17] Shareholder Returns - Approximately $4.1 billion has been returned to shareholders from 2016 to 2025 YTD in the form of dividends and share repurchases[45, 46, 47] - From January 1, 2025, to May 7, 2025, Melco repurchased 32.3 million ADSs for approximately $165 million[47]

Financial Performance - The company generated an operating profit of HK$1.75 billion, a 10.6% year-over-year increase[4, 51] - Value-added Services (VAS) revenue increased by 2.1% year-over-year to HK$3.73 billion[50] - The company's full-year dividend per share remained stable at HK$ 0.50[4, 90] - Revenue decreased by 2.6% year-over-year to HK$79.258 billion[90] - Profit for the year increased by 8.7% year-over-year to HK$4.190 billion[90] - Free cash flow reached HK$4.66 billion, an 8.7% increase compared to the previous year[93] Natural Gas Business - Natural gas sales volume decreased by 4.2% year-over-year[8] - Residential natural gas sales volume increased by 3.7% year-over-year[8] - The average dollar margin for city & township projects increased from RMB 0.501/m³ to RMB 0.537/m³[15] LPG Business - LPG sales volume decreased by 3.2% year-over-year to 3.868 million tons[30] - LPG revenue increased by 8.9% year-over-year to HK$19.5755 billion[30, 90] Connections - New residential connections decreased by 15.5% year-over-year to 1,400,521 users[22] - New commercial connections increased by 46.1% year-over-year to 44,206 users[22]

Financial Performance - Revenue reached HK$13,341 million[8] - Operating profit was HK$1,412 million, a decrease of 33.3% year-over-year[8,10] - Profit attributable to equity holders amounted to HK$1,100 million, down 37.8%[8] - Adjusted operating profit (excluding gold hedging losses) was HK$1,904 million, up 14.8%[8] - Basic earnings per share were HK$1.87, a decrease of 37.9%[8] Dividends - Annual dividend per share was HK$1.10[8] - Dividend payout ratio was 59%[8] - Proposed final dividend per share is HK$0.55[8] Key Financial Indicators - Inventories increased to HK$10,739 million, a rise of 12.2%[18] - Net cash/ (borrowing) was -HK$205 million, a decrease of 135.9%[18] - Average inventory turnover days increased to 427 days[18] Revenue Breakdown - Revenue from Hong Kong, Macau & Overseas was HK$8,068 million[22] - Revenue from Mainland China was HK$5,273 million[22] - Retailing revenue was HK$11,031 million[25] - Wholesaling revenue was HK$1,406 million[25] - Licensing revenue was HK$904 million[25]

Financial Performance - Revenue increased by 11.6% to RMB 25,901.7 million in FY2024/25 [8, 14] - Profit attributable to equity holders of the Company increased by 14.3% to RMB 3,513.9 million [8] - Basic earnings per share increased by 11.4% to RMB 31.58 cents [8] - The Group's gross profit margin decreased by 2.3 percentage points to 57.3% [9] Revenue Breakdown - Branded down apparel revenue increased by 11.0% to RMB 21,668.2 million, accounting for 83.7% of total revenue [14, 16] - OEM management revenue increased significantly by 26.4% to RMB 3,373.4 million, representing 13.0% of total revenue [14, 16] - Ladieswear apparel revenue decreased by 20.6% to RMB 651.1 million, accounting for 2.5% of total revenue [14, 16] Branded Down Apparels Business - Bosideng brand revenue increased by 10.1% to RMB 18,481.0 million [17] - Snow Flying brand revenue increased by 9.2% to RMB 2,205.5 million [17] - Online sales of branded down apparel increased to RMB 7,478.2 million [79] Ladieswear Apparels Business - Ladieswear apparel revenue decreased by 20.6% to RMB 651.1 million [16, 92] - Revenue from online sales was RMB 97.2 million [92]